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9-([2-Hydroxy-l-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) is more potent and has a more
prolonged inhibitory effect against Epstein-Barr virus (EBV) in vitro than does acyclovir (ACV). To assess the
mechanism of this difference, we first compared the extent of phosphorylation of the two drugs in superinfected
Raji cells. BW B759U is phosphorylated to levels 100-fold higher than is ACV. In addition, lower levels of
phosphorylation of BW B759U and ACV were observed in uninfected Raji cells. Studies on the kinetics of
formation of BW B759U triphosphate in superinfected Raji cells indicated that drug-phosphorylating activity
was detected as early as 3 h after superinfection; this activity was steadily maintained for the first 7 h, followed
by a burst of activity between 7 and 10 h and a doubling of phosphorylation between 10 and 25 h. During the
superinfection cycle, the pool sizes of deoxyribonucleoside and ribonucleoside triphosphates were increased and
reached their maxima at 10 h after infection. The maximal amount of triphosphorylated drug in a virus
producer cell, P3HR-1 (LS), was obtained at 21 h after drug treatment. During long-term drug treatment,
approximately 44 and 77% reduction in EBV genome copies per cell was observed on days 3 and 7,
respectively. In a separate experiment, after treatment of P3HR-1 (LS) cells with BW B759U for 36 h, 4.2 pmol
of BW B759U triphosphate per 106 cells was achieved. After the cells were released into drug-free medium,
drug triphosphate was rapidly decreased to 11% of the original level in 1 day. Thereafter, the decrease was slow
but steady, down to 0.22 pmol/106 P3HR-1 cells by 5 days. We calculated that 0.22 pmol of BW B759U
triphosphate per 106 cells represents a cellular concentration of 0.22 ,uM, which is theoretically enough to
inhibit EBV replication. This is based upon a comparison with the 50% effective dose ofBW B759U (0.05 ,IM)
for inhibition of genome replication and a Ki of 0.08 I,M for BW B759U triphosphate inhibition of EBV DNA
polymerase.
An acyclovir (ACV) congener, 9-([2-hydroxy-1-(hy-
droxymethyl)ethoxy]methyl)guanine (BW B759U or
DHPG), is active in vitro against herpes simplex virus types
1 and 2 (HSV-1 and HSV-2), Epstein-Barr virus (EBV), and
human cytomegalovirus (5, 9, 17-19, 23). We recently dem-
onstrated that BW B759U has more-prolonged effects than
ACV in suppressing EBV replication, even after the drug is
removed from persistently infected cell cultures (17). We
have also reported preliminary evidence that BW B759U is
more efficiently phosphorylated than ACV in EBV-infected
cells (13). The initial step in the antiviral action of BW
B759U against HSV evidently involves its selective phos-
phorylation in infected cells (1, 23), and the herpesvirus-
specified DNA polymerase is subsequently inhibited by the
drug 5'-triphosphate (10, 12, 24).
To understand the molecular mechanisms of prolonged
inhibition of EBV replication by BW B759U, we studied the
extent of phosphorylation of this drug in superinfected Raji
cells and in a virus-producing cell line, P3HR-1. The results
indicate that BW B759U, in contrast to ACV, is preferen-
tially phosphorylated in human lymphoblastoid cell lines
infected with EBV and that the triphosphate of BW B759U
persists at a significant level for 5 days after drug removal.
The implications of these findings are discussed.
* Corresponding author.
MATERIALS AND METHODS
Cell cultures. Virus-nonproducer (Raji) cells were main-
tained between 2 x 105 and 1 x 106 cells per ml in tissue
culture flasks in RPMI 1640 medium containing 10% fetal
calf serum supplemented with 100 IU of penicillin per ml and
100 ,ug of streptomycin per ml. Virus-producer (P3HR-1)
cells were grown in the same medium as Raji cells, except
that the cells were gradually adapted to growth in low-serum
medium (1.5% fetal calf serum). Under these conditions,
approximately 20 to 50% of the cells are spontaneously
activated to produce virus (unpublished data), as routinely
monitored by the indirect immunofluorescence assay for
EBV antigens. This cell line, designated P3HR-1 (LS), has
maintained a highly virus-productive state for more than 18
months under these low-serum conditions. Cells were
seeded at a density of 4 x 105 to 6 x 105 cells per ml and were
counted daily until they reached a density of 3 x 106 cells per
ml. During this interval, the cells grew exponentially (15).
Radioactive drugs. [8-14C]BW B759U (50 mCi/mmol) and
[8-14C]ACV (53.8 mCi/mmol) were prepared in the Wellcome
Laboratories. Both compounds also contained approxi-
mately 2% [8-14C]guanine.
Treatment of P3HR-1 (LS) cells with drug. Exponentially
growing P3R-1 (LS) cells were centrifuged and suspended in
fresh medium containing 100 ,uM [14C]BW B759U for the
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TABLE 1. Formation of BW B759U- and ACV-triphosphate in
EBV-superinfected Raji cells
Drug EBV [14C]Drug triphosphateDrug infection (pmol106 cells)
[14C]BW B759U Yes 11
[14C]ACV Yes <0.1
[14C]BW B759U No 2.3
[14C]ACV No <0.1
indicated times. Aliquots of the cell suspension (3 x 107
viable cells) were taken at each time interval, and perchloric
acid extracts were prepared. In parallel with these experi-
ments, aliquots of cell samples were also taken on days 0, 1,
3, and 7 for determination ofEBV genome copy numbers per
cell by cRNA-DNA hybridization (16).
In a separate experiment, exponentially growing P3HR-1
(LS) cells were treated with 100 FXM [14C]BW B759U for 36
h and then washed and released into drug-free medium.
Aliquots of cell samples were taken 0, 1, 3, and 5 days after
drug removal.
Superinfection of Raji cells with P3HR-1 (LS) virus and
drug treatment. Virus used for superinfection of Raji cells
was prepared from 12-O-tetradecanoylphorbol-13-acetate-
induced P3HR-1 (LS) culture fluids (14). Virus was har-
vested by centrifugation (13,000 x g for 90 min in a GS-3
rotor), suspended in RPMI 1640 medium containing 2% fetal
calf serum, and stored at -70°C. For superinfection, 2 x 107
cells in exponential growth were pelleted and suspended in 6
ml of EBV preparation (time zero). After 1 h at 37°C in a CO2
incubator, the cells were pelleted, washed twice with me-
dium, resuspended in 10 ml of medium containing 30 or 100
,uM of [14C]BW B759U (50 ,uCi/,umol) or [14C]ACV (53.8
iLCi/4mol), and incubated for the specified times.
Perchloric acid extraction. Perchloric acid extraction was
done as described in reference 8. The superinfected cells
were harvested and washed three times with cold phosphate-
buffered saline solution. Then the cell pellets were sus-
pended in 9 volumes of ice-cold 3.5% perchloric acid (PCA).
Approximately 10,000 dpm of [3H]dTTP was added to each
sample to monitor the recovery. The samples were placed on
ice for 30 min and then centrifuged at 10,000 rpm for 20 min
in a Sorvall HB-4 rotor. The PCA-soluble fractions were
immediately neutralized with KOH, and the potassium
perchlorate precipitates were removed by centrifugation.
HPLC analysis. The neutralized PCA-soluble fractions
were evaporated to dryness and dissolved in distilled water.
Anion-exchange high-pressure liquid chromatography
(HPLC) on a Whatman Partisil PXS10 or 10 SAX column
was used to separate nucleotides. Separation of ribo-
nucleotides was carried out by elution with a linear gradient
of from 0.3 to 0.8 M KH2PO4, pH 3.5, at a flow rate of 1
ml/min. For analysis of deoxyribonucleoside triphosphates,
cell extracts were treated with sodium periodate and meth-
ylamine to remove ribonucleotides (11) and acidified to pH 4
to prevent dGTP degradation. Elution was performed with
the same linear gradient used for separation of ribonucleo-
side triphosphates, except that the pH was 3.8. BW B759U
triphosphate (BW B759U-TP) concentrations were calcu-
lated from the radioactivity in HPLC fractions. These frac-
tions were collected for 1 min each and counted in a
Beckman LS-335 liquid scintillation system. This HPLC
system clearly separated GTP, BW B759U-TP, 2'-dGTP,
and ACV triphosphate (ACV-TP) (26.6, 27.2, 28.4, and 41.9
min, respectively).
RESULTS
Phosphorylation of BW B759U and ACV in superinfected
and mock-infected Raji cells. To assess the molecular mech-
anism of the higher activity of BW B759U and to gain a
preliminary understanding of the more-prolonged inhibitory
effect ofBW B759U over ACV (17), we compared the extent
of phosphorylation of these drugs in superinfected Raji cells
(Table 1). Exponentially growing Raji cells were mock-
infected or superinfected with EBV, 100 ,uM [14C]BW
B759U or [14C]ACV was added at 8 h after infection, and
incubation was continued for 4 h. EBV infection produced a
marked increase in phosphorylation ofBW B759U ([14C]BW
B759U-TP level, 11 pmol/106 cells); this phosphorylation
was much greater than with ACV ([14C]ACV-TP level, <0.1
pmol/106 cells). Levels of BW B759U-TP were five times
higher in infected than in uninfected cells ([14C]BW B759U
level in uninfected cells, 2.3 pmol/106 cells), but ACV-TP
concentrations did not increase with infection ([14C]ACV-TP
level in uninfected cells, <0.1 pmol/106 cells). These results
indicate that BW B759U is more efficiently phosphorylated
than ACV and that the increase in drug-phosphorylating
activity is associated with EBV infection.
Kinetics of formation of BW B759U-TP in superinfected
Raji cells. We next decided to determine the kinetics of
formation ofBW B759U-TP in superinfected Raji cells. At 1
h after superinfection, [14C]BW B759U (30 ,uM) was added,
and aliquots of cells were taken at various time intervals for
HPLC analysis. An increase in drug-phosphorylating activ-
ity can be detected as early as 3 h after superinfection (2 h
after drug addition) (Fig. 1); this activity was steadily main-
tained for the first 7 h. Between 7 and 10 h a rapid elevation
of the BW B759U-TP level occurred, followed by a doubling
of the BW B759U-TP level between 10 and 25 h postinfec-
tion. The concentration at 25 h was 20-fold greater than at 3
h after infection. These results clearly indicate that BW
B759U-TP accumulated in infected cells as a function of
exposure time to the drug during this phase of the superin-
fection cycle.
Deoxyribonucleoside and ribonucleoside triphosphate levels
in superinfected Raji cells in the presence of BW B759U. In
parallel with the kinetics experiment depicted in Fig. 1, we
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FIG. 1. Kinetics of formation ofBW B759U-TP in superinfected
Raji cells. At 1 h after superinfection of Raji cells, 30 ,uM [14C]BW
B759U was added and aliquots of cells were taken at various
intervals for HPLC analysis.
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FIG. 2. Deoxyribonucleoside triphosphate levels in super-
infected Raji cells in the presence of 30 ,uM ['4C]BW B759U. In
parallel with the experiment shown in Fig. 1, the pool sizes of
deoxyribonucleoside triphosphates were analyzed by HPLC.
and ribonucleoside triphosphates during the infection cycle.
Superinfection of Raji cells resulted in a severalfold increase
in deoxyribonucleotide pools, with dTTP reaching the high-
est concentration. The pool levels increased steadily up to 9
h, and a maximum occurred between 9 and 24 h after
infection for all of the pools (Fig. 2). Ribonucleoside triphos-
phate pool sizes were also measured. The levels of the
ribonucleoside triphosphates CTP, UTP, ATP, and GTP
increased similarly with time during the infection cycle
(Table 2). CTP, UTP, and ATP levels increased approxi-
mately threefold, but the GTP level changed only slightly.
Treatment of superinfected Raji cells with BW B759U does
not cause changes in deoxyribonucleoside and ribonucleo-
side triphosphate pool levels over the changes caused by
infection alone (data not shown).
Determination of optimum duration of drug treatment. To
gain insight into the persistent effect of BW B759U in
inhibition of EBV genome replication in P3HR-1 (LS) cells
(17), we first determined the optimum duration of drug
treatment that produced maximum amounts ofBW B759-TP.
The phosphorylated drug can be detected as early as 4 h after
drug addition at 30 ,uM; the maximum formation of drug
triphosphate occurred at 21 h (Fig. 3B). At the same times,
the levels of deoxyribonucleoside triphosphates were below
the limits of detection by HPLC (less than 2 pmol/106 cells).
The effect of the drug on EBV genome replication is shown
in Fig. 3A. No significant difference in EBV genome copies
per cell was observed 1 day after drug treatment. Approxi-
mately 44 and 77% reduction in EBV genome copies per cell
was observed on days 3 and 7, respectively, probably owing
TABLE 2. Ribonucleoside triphosphate levels in superinfected
Raji cells in the presence of BW B759U
Time Amt (pmol/106 cells) of:
postinfection (h) CTP UTP ATP GTP
2 425 1,426 4,386 3,008
4 421 1,475 5,011 2,054
6 569 2,229 6,338 2,144
9 1,310 4,338 11,813 3,933
24 1,069 2,923 6,834 2,930
1 2 3 4 7
TIME (DAY)
FIG. 3. Biochemical effects of 30 FM ['4C]BW B759U on
P3HR-1 (LS) cells. (A) Kinetics of reduction of viral genome
replication; (B) kinetics of formation of [14C]BW B759U-TP.
to cell division and elimination of productive cell popula-
tions.
Persistent presence of BW B759U-TP in P3HR-1 (LS) cells
after drug removal. The levels of drug triphosphate at
various times after drug removal were examined. Approxi-
mately 4.2 pmoles of BW B759U-TP per 106 cells was
achieved after 36 h of treatment with the drug at 100 ,uM
(Fig. 4). After the cells had been washed and released into
drug-free medium, the initial drop of drug triphosphate level
was very rapid, down to 11% of the original level after 1 day.
Thereafter, the decrease was slow but steady, and the
intracellular concentration of BW B759U-TP reached 0.22












DAYS AFTER DRUG REMOVAL
FIG. 4. Persistence of [14C]BW B759U-TP in P3HR-1 (LS) cells
after drug removal. Cell pellets extracted with PCA were analyzed
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DISCUSSION
In a previous study, we demonstrated that BW B759U is
more potent and has a more prolonged inhibitory effect than
ACV against EBV (17). In that study, however, we did not
elucidate the molecular mechanism underlying this differ-
ence. As for other nucleoside analogs, it has been postulated
that BW B759U might be preferentially phosphorylated in
EBV-infected cells in contrast to the low level of phosphor-
ylation in uninfected cells (2, 9, 22). Our results support this
premise and show that ACV is very inefficiently phosphory-
lated in EBV-infected cells. The more efficient phosphory-
lation of BW B759U than of ACV has been observed in
HSV- and cytomegalovirus-infected cells as well (2, 12).
In wild-type HSV-1-infected Vero cells, there was 10-fold
more phosphorylation ofBW B759U than of ACV, but the Ki
for DNA polymerase was also 10-fold higher for BW B759U-
TP than for ACV-TP, resulting in comparable 50% inhibitory
dose values for the two drugs (24). For the DNA polymerase
of EBV, the Ki of BW B759U-TP was 0.08, 11 times higher
than that reported for ACV-TP under the same conditions
(6). This is similar to the fivefold-higher Ki for BW B759U-
TP than for ACV-TP that is seen with HCMV DNA poly-
merase (2). However, both EBV and HCMV are more
strongly inhibited by BW B759U. In both cases, the prefer-
ential intracellular formation of BW B759U-TP over ACV-
TP is sufficient to outweigh the difference in Kis.
The study on the kinetics of formation of BW B759U-TP in
superinfected Raji cells indicated that there is a stable pool
of drug triphosphate accumulated up to 24 h after infection
and drug treatment (Fig. 1). It appears that the triphosphate
of BW B759U, once formed, is relatively stable and is
conserved within the cells.
There is some evidence against the existence of an EBV-
specific thymidine kinase (7, 21). However, other evidence
indicates that there is a novel enzyme activity induced by
EBV that might represent a virally encoded thymidine
kinase (3, 20, 25). Despite these discrepancies, we found that
BW B759U, in contrast to ACV, is preferentially phos-
phorylated in superinfected Raji cells compared with mock-
infected cells. Whether the low level of phosphorylation of
BW B759U in mock-infected cells is carried out by the same
enzyme as in superinfected Raji cells remains to be deter-
mined.
The level of BW B759U-TP that was achieved in P3HR-1
(LS) cells after 36 h of treatment with the drug at 100 ,uM was
4.2 pmol/106 cells (Fig. 3), which is low compared with that
achieved in superinfected Raji cells with less drug and
shorter times. On the basis of the measured cell volume, 1
iuiI106 cells, we calculated that the initial concentration of
BW B759U-TP in the P3HR-1 (LS) cells was 4.2 ,uM before
drug removal and 0.22 ,uM 5 days after drug removal. These
concentrations were sufficient to inhibit EBV replication,
compared with the 50% effective dose of BW B759U (0.05
,uM) for the inhibition of EBV genome replication (17) and
with the Ki (0.08 ,uM) of BW B759U-TP for EBV DNA
polymerase (6). On the basis of the rate of decrease of the
BW B759U-TP level in the cells between days 1 and 5 after
drug removal (Fig. 4), we predict that it would have taken
more than 2 weeks for the BW B759U-TP to diminish below
the concentration required for effective inhibition (<0.08
,uM) of the EBV polymerase. The persistence ofBW B759U-
TP in P3HR-1 (LS) cells for 5 days after drug removal may
account for the prolonged inhibitory effect of BW B759U
observed previously (17).
In contrast with ACV, which is a chain terminator only
(8), internal incorporation of BW B759U into viral DNA
strands as well as at termini was observed in HSV-infected
cells (4). Since much more BW B759U-TP is formed than
ACV-TP in superinfected Raji cells, much more BW B759U-
TP is available for incorporation into DNA. This would
account for the greater sensitivity of EBV to BW B759U
than to ACV. BW B759U-TP competes with dGTP for
incorporation catalyzed by HSV-1 DNA polymerase (10).
When dGTP is low, as in P3HR cells (unpublished data), the
levels of BW B759U-TP described in this experiment should
be able to compete for incorporation into EBV DNA. These
metabolic results could add to the more prolonged inhibition
of EBV by BW B759U than by ACV.
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